Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Fellowship - PA: CIHR/Rx&D - CAMO Research Program

University of Toronto

$55,000.00

Evaluating the anti-tumor activity of a dual IGF-1R and IR inhibitor (OSI-906) in genomically characterized human breast cancer (BC) xenograft models.

FY 2010-11

Summary
Breast cancer is the most common cancer diagnosed in Canadian women (excluding non-melanoma skin cancer). Despite advances in early detection and treatment, breast cancer remains the second-leading cause of cancer death in Canadian women. There is an urgent need to develop improved therapies for women with advanced breast cancer. OSI-906 is a promising new drug that blocks two critical pathways involved in breast cancer growth and resistance to existing treatments, the Insulin Growth Factor-1 Receptor (IGF-1R) and the Insulin Receptor (IR). The aim of this project is to test OSI-906, either alone or in combination with other promising new drugs, in mouse models implanted with samples of breast tumors donated by women with advanced breast cancer. This will provide a better understanding of which types of breast cancer are likely to benefit from treatment with OSI-906 either alone or in combination with other promising new drugs that can be tested in future clinical trials involving patients with breast cancer.
Program
Fellowship - PA: CIHR/Rx&D - CAMO Research Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
215847
Name
Sahebjam Solmaz
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Medical Oncologists (Ottawa)
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Evaluating the anti-tumor activity of a dual IGF-1R and IR inhibitor (OSI-906) in genomically characterized human breast cancer (BC) xenograft models.
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$55,000
Cihrequipment2
$0
Programname2
Fellowship - PA: CIHR/Rx&D - CAMO Research Program
Keyworddelim
Breast Cancer; Dual Inhibitor Of Igf-1r And Ir; Patient-Derived Human Tumor Xenografts; Predictive Markers; Targeted Agents; Targeted Sequencing
Abstract
Breast cancer is the most common cancer diagnosed in Canadian women (excluding non-melanoma skin cancer). Despite advances in early detection and treatment, breast cancer remains the second-leading cause of cancer death in Canadian women. There is an urgent need to develop improved therapies for women with advanced breast cancer. OSI-906 is a promising new drug that blocks two critical pathways involved in breast cancer growth and resistance to existing treatments, the Insulin Growth Factor-1 Receptor (IGF-1R) and the Insulin Receptor (IR). The aim of this project is to test OSI-906, either alone or in combination with other promising new drugs, in mouse models implanted with samples of breast tumors donated by women with advanced breast cancer. This will provide a better understanding of which types of breast cancer are likely to benefit from treatment with OSI-906 either alone or in combination with other promising new drugs that can be tested in future clinical trials involving patients with breast cancer.
Competitiondate
201010
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Sahebjam, Solmaz
Approvedterm
2 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $55,000~ $0~